Extracellular Signal–Regulated Kinase 1/2 Regulates Mouse Kidney Injury Molecule-1 Expression Physiologically and Following Ischemic and Septic Renal Injury

Justin B. Collier and Rick G. Schnellmann

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina (J.B.C.); and Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona (R.G.S.)

Received July 21, 2017; accepted September 27, 2017

ABSTRACT

The upregulation of kidney injury molecule-1 (KIM-1) has been extensively studied in various renal diseases and following acute injury; however, the initial mechanisms controlling KIM-1 expression remain limited. In this study, KIM-1 expression was examined in mouse renal cell cultures and in two different models of acute kidney injury (AKI), ischemia reperfusion (IR)– and lipopolysaccharide (LPS)–induced sepsis. KIM-1 mRNA increased in both AKI models, and pharmacological inhibition of extracellular signal–regulated kinase 1/2 (ERK1/2) signaling attenuated injury–induced KIM-1 expression in the renal cortex. Toll-like receptor 4 knockout (TLR4KO) mice exhibited reduced ERK1/2 phosphorylation and at a physiologic level.

Visual Abstract. Proposed mechanism of IR, LPS, and ROS–induced renal damage that initiates ERK1/2 and STAT3 phosphorylation. STAT3 then binds to the KIM-1 promoter and increases KIM-1 mRNA. By preventing ERK1/2 phosphorylation following renal injury, STAT3 phosphorylation of signal transducer and activator of transcription 3 (STAT3) at serine 727 and tyrosine 705 increased downstream from ERK1/2 activation. Because phosphorylated STAT3 is a transcriptional upregulator of KIM-1 and inhibition of ERK1/2 attenuated increases in STAT3 phosphorylation, we suggest an ERK1/2-STAT3-KIM-1 pathway following renal injury. Finally, ERK1/2 inhibition in naive mice decreased KIM-1 mRNA and nuclear STAT3 phosphorylation in the cortex, indicating homeostatic regulation of KIM-1. These findings reveal renal ERK1/2 as an important initial regulator of KIM-1 expression in IR and septic AKI and at a physiologic level.

Introduction

Kidney injury molecule-1 (KIM-1) is a type I transmembrane glycoprotein that is rapidly upregulated at the gene and protein level following various types of injury to the kidney (Ichimura et al., 1998; Amin et al., 2004; Vaidya et al., 2010). For example, KIM-1 is increased in injuries induced by ischemia reperfusion (IR), cisplatin, sepsis, folic acid, aristolochic acid, and gentamicin, and occurs in disease states such as renal cell carcinoma, polycystic kidney disease, hyperoxaluria, and hypertension (Han et al., 2005; Ichimura and Mou, 2008; Khandrika et al., 2012; Tian et al., 2017).

The ectodomain, which contains an Ig-like domain and a glycosylated mucin domain, is cleaved by the metalloprotease ADAM17 at the cellular membrane (Ichimura et al., 1998; Bailly et al., 2002; Gandhi et al., 2014). Membrane bound KIM-1 and cleaved KIM-1 increase with worsening renal injury (Zhang et al., 2007). KIM-1 is located on the apical surface of renal proximal tubule epithelial cells and recognizes phosphatidylserine and oxidized lipoprotein epitopes on the surface of apoptotic bodies (Ichimura et al., 2008).

Extracellular signal–regulated kinase 1/2 (ERK1/2) is a mitogen-activated protein kinase that is phosphorylated rapidly following renal injury (Masaki et al., 2003, 2004; Arany et al., 2004). We previously demonstrated ERK1/2 phosphorylation is elevated 3 hours post IR injury and 1 hour post lipopolysaccharide (LPS)–induced acute kidney injury (AKI) (Smith et al., 2015; Collier et al., 2016). Further exploration of the ERK1/2 pathway was performed utilizing a specific mitogen-activated protein kinase kinase 1/2 inhibitor, trametinib, which inhibits the increase in ERK1/2 phosphorylation since mitogen-activated protein kinase kinase 1/2 is directly upstream of ERK1/2 (Gilmartin et al.,
Interestingly, inhibiting LPS-induced ERK1/2 phosphorylation prevented KIM-1 mRNA upregulation after 3 and 18 hours post LPS administration. Smith et al. (2016) confirmed ERK1/2 inhibition attenuates the upregulation of KIM-1 mRNA following injury utilizing trametinib treatment 6 hours post cecal ligation and puncture surgery, a model of sepsis.

ERK1/2 and KIM-1 were studied in vitro using a porcine kidney epithelial cell line, LLC-PK1, transfected with human KIM-1 (Zhang and Cai, 2016). KIM-1 protein promoted cell migration and proliferation through activation of the ERK1/2 pathway, and inhibiting ERK1/2 attenuated these processes. Recently, KIM-1 was shown to modulate macrophages by promoting an M1 phenotype and macrophage migration by mitogen-activated protein kinase pathways, including ERK, p38, and c-Jun N-terminal kinase (Tian et al., 2017). It is clear that ERK1/2 and KIM-1 are activated and upregulated shortly after kidney injury; however, a direct connection between ERK1/2 and KIM-1 has received limited study.

Ajay et al. (2014) used a combination of bioinformatics, in vitro, and in vivo experiments to determine that phosphorylation of signal transducer and activator of transcription 3 (STAT3) at serine 727 (S727) and tyrosine 705 (Y705) increases KIM-1 transcription by binding to the KIM-1-specific promoter. Checkpoint kinase 1 (Chk1) was upregulated following IR injury due to DNA damage, which phosphorylated STAT3 and subsequently regulated KIM-1 expression (Ajay et al., 2014). Interestingly, ERK2 was the most enriched upstream kinase identified that was associated with the highest upregulated transcription factors following IR injury (Berger et al., 2007; Lachmann and Maayan, 2009; Ajay et al., 2014). Given this information and our previous data demonstrating ERK1/2 is rapidly phosphorylated post IR injury, we hypothesized early ERK1/2 activation following injury preferentially regulates KIM-1 expression.

**Materials and Methods**

**In Vitro.** A transgenic kidney proximal tubule (TKPT) cell line originally isolated from 8Tg(SV40E)Bri7 mice and developed by Ernest and Bello-Reuss (1995) was used in all in vitro experiments (MacKay et al., 1988). TKPT cells were grown in 35-mm tissue culture dishes. The culture medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12 (without phenol red or sodium pyruvate) supplemented with 5 mM glucose, 10% fetal bovine serum, 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 mM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 

**Immunoblot Analysis.** Protein was extracted from renal cortex tissue with TRIzol reagent (Life Technologies, Carlsbad, CA). The iScript Advanced cDNA Synthesis Kit (Bio-Rad, Hercules, CA) was used according to the manufacturer’s protocol. The generated cDNA was used with the SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA expression of all genes was determined by the 2−ΔΔCt method, and mouse actin RNA and rabbit tubulin RNA were used as reference genes for normalization. The KIM-1 primer sequences used were forward: 5′-GCATCTTAAAGCGTGGTTGCC-3′ and reverse: 5′-TACGCTTCGGGAAATGCACAAC-3′.

**In Vivo.** A transgenic kidney proximal tubule (TKPT) cell line originally isolated from 8Tg(SV40E)Bri7 mice and developed by Ernest and Bello-Reuss (1995) was used in all in vitro experiments (MacKay et al., 1988). TKPT cells were grown in 35-mm tissue culture dishes. The culture medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12 (without phenol red or sodium pyruvate) supplemented with 5 mM glucose, 10% fetal bovine serum, 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 mM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 

**Materials and Methods**

**In Vitro.** A transgenic kidney proximal tubule (TKPT) cell line originally isolated from 8Tg(SV40E)Bri7 mice and developed by Ernest and Bello-Reuss (1995) was used in all in vitro experiments (MacKay et al., 1988). TKPT cells were grown in 35-mm tissue culture dishes. The culture medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12 (without phenol red or sodium pyruvate) supplemented with 5 mM glucose, 10% fetal bovine serum, 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 mM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 

**Immunoblot Analysis.** Protein was extracted from renal cortex tissue with TRIzol reagent (Life Technologies, Carlsbad, CA). The iScript Advanced cDNA Synthesis Kit (Bio-Rad, Hercules, CA) was used according to the manufacturer’s protocol. The generated cDNA was used with the SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA expression of all genes was determined by the 2−ΔΔCt method, and mouse actin RNA and rabbit tubulin RNA were used as reference genes for normalization. The KIM-1 primer sequences used were forward: 5′-GCATCTTAAAGCGTGGTTGCC-3′ and reverse: 5′-TACGCTTCGGGAAATGCACAAC-3′.

**In Vivo.** A transgenic kidney proximal tubule (TKPT) cell line originally isolated from 8Tg(SV40E)Bri7 mice and developed by Ernest and Bello-Reuss (1995) was used in all in vitro experiments (MacKay et al., 1988). TKPT cells were grown in 35-mm tissue culture dishes. The culture medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12 (without phenol red or sodium pyruvate) supplemented with 5 mM glucose, 10% fetal bovine serum, 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 mM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 

**Immunoblot Analysis.** Protein was extracted from renal cortex tissue with TRIzol reagent (Life Technologies, Carlsbad, CA). The iScript Advanced cDNA Synthesis Kit (Bio-Rad, Hercules, CA) was used according to the manufacturer’s protocol. The generated cDNA was used with the SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA expression of all genes was determined by the 2−ΔΔCt method, and mouse actin RNA and rabbit tubulin RNA were used as reference genes for normalization. The KIM-1 primer sequences used were forward: 5′-GCATCTTAAAGCGTGGTTGCC-3′ and reverse: 5′-TACGCTTCGGGAAATGCACAAC-3′.

**Materials and Methods**

**In Vitro.** A transgenic kidney proximal tubule (TKPT) cell line originally isolated from 8Tg(SV40E)Bri7 mice and developed by Ernest and Bello-Reuss (1995) was used in all in vitro experiments (MacKay et al., 1988). TKPT cells were grown in 35-mm tissue culture dishes. The culture medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12 (without phenol red or sodium pyruvate) supplemented with 5 mM glucose, 10% fetal bovine serum, 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 mM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 

**Immunoblot Analysis.** Protein was extracted from renal cortex tissue with TRIzol reagent (Life Technologies, Carlsbad, CA). The iScript Advanced cDNA Synthesis Kit (Bio-Rad, Hercules, CA) was used according to the manufacturer’s protocol. The generated cDNA was used with the SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA expression of all genes was determined by the 2−ΔΔCt method, and mouse actin RNA and rabbit tubulin RNA were used as reference genes for normalization. The KIM-1 primer sequences used were forward: 5′-GCATCTTAAAGCGTGGTTGCC-3′ and reverse: 5′-TACGCTTCGGGAAATGCACAAC-3′.

**Immunoblot Analysis.** Protein was extracted from renal cortex tissue with TRIzol reagent (Life Technologies, Carlsbad, CA). The iScript Advanced cDNA Synthesis Kit (Bio-Rad, Hercules, CA) was used according to the manufacturer’s protocol. The generated cDNA was used with the SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA expression of all genes was determined by the 2−ΔΔCt method, and mouse actin RNA and rabbit tubulin RNA were used as reference genes for normalization. The KIM-1 primer sequences used were forward: 5′-GCATCTTAAAGCGTGGTTGCC-3′ and reverse: 5′-TACGCTTCGGGAAATGCACAAC-3′.
bovine serum albumin or 5% milk in Tris-buffered saline/Tween 20 and incubated overnight with primary antibody at 4°C with gentle agitation. The primary antibodies used in these studies included phospho-ERK1/2 (1:1000), total ERK1/2 (1:1000), phospho-Chk1 (1:1000), Chk1 (1:1000), phospho-STAT3-Tyr705 (1:1000), phospho-STAT3-Ser727 (1:1000), total STAT3 (1:1000), and histone H3 (1:2000) from Cell Signaling Technology, Danvers, MA; lamin B1 (1:1000; Abcam, Cambridge, United Kingdom), phospho-Chk1 (1:900), and KIM-1 (1:1000) from R&D Systems, Minneapolis, MN; and β-actin (1:2000) from Santa Cruz Biotechnology, Dallas, TX.

Membranes were incubated with the appropriate horseradish peroxidase–conjugated secondary antibody before visualization using enhanced chemiluminescence (Thermo Scientific, Waltham, MA) and GE ImageQuant LAS4000 (GE Life Sciences; Marlborough, MA). Optical density was determined using the ImageJ software from the National Institutes of Health (Bethesda, MD) and Image Studio Lite from LI-COR (Lincoln, NE).

### Statistical Analysis
All data are shown as mean ± S.E.M. When comparing two experimental groups, an unpaired, two-tailed t test or Mann-Whitney U test was used to determine statistical differences. A one-way analysis of variance followed by Tukey’s post hoc test was performed for comparisons of multiple groups. P < 0.05 was considered statistically significant. All statistical tests were performed using GraphPad Prism software (GraphPad Software, San Diego, CA).

### Results

**ERK1/2 Increases KIM-1 mRNA Following Toxicant Exposure in Mouse Renal Cells.** To confirm that KIM-1 expression is upregulated following toxicant exposure, cultured mouse TKPT cells were treated with 1 and 10 mM HU, 0.1 and 1 mM hydrogen peroxide (H$_2$O$_2$), and 350 and 700 μM TBHP for 24 hours. HU causes cellular injury by inhibiting DNA synthesis and causing DNA damage (Singh and Xu, 2016), while H$_2$O$_2$ and TBHP are model oxidants that lead to oxidative stress causing protein, lipid, and DNA damage (Nowak et al., 2006). Each toxicant increased KIM-1 mRNA with increasing concentration (Fig. 1A). KIM-1 mRNA increased 8-, 3-, and 3-fold in response to 10 mM HU, 1 mM H$_2$O$_2$, and 700 μM TBHP, respectively (Fig. 1A). A 1-hour pretreatment with trametinib prevented HU-, H$_2$O$_2$-, and TBHP-induced KIM-1 mRNA increases (Fig. 1B). Interestingly, TKPT cells treated with trametinib alone showed a 54% decrease in KIM-1 mRNA compared with vehicle control cells after 24 hours (Fig. 1B). These data reveal a regulatory role for ERK1/2 on KIM-1 mRNA under control conditions and following DNA and oxidative damage.

**Early ERK1/2 Activation Mediates STAT3 Phosphorylation-Induced KIM-1 mRNA Upregulation Following IR AKI.** KIM-1 mRNA increased 4.7-fold 3 hours post IR AKI compared with sham controls (Fig. 2A). Trametinib attenuated the KIM-1 mRNA and SCr increases when administered 1 hour before IR surgery (Fig. 2, A and B). The phosphorylated ERK1/2 to total ERK1/2 ratio increased 4.5-fold in the IR groups compared with the sham groups (Fig. 2, C and D). Trametinib also completely inhibited ERK1/2 phosphorylation increases following AKI, as observed previously (Smith et al., 2015; Collier et al., 2016). Ajay et al. (2014) reported that Chk1 phosphorylation is elevated 3 hours post IR AKI. In contrast, we did not observe any change in phosphorylated Chk1 to total Chk1 ratio following IR injury in the presence or absence of trametinib. However, transcription factor STAT3 phosphorylation at both activating sites, S727 and Y705, increased 2.5- and 3.5-fold after renal IR, respectively (Fig. 2, C and E–H) and pretreatment with trametinib partially blocked the increase in phosphorylation of STAT3 at S727 and Y705 (Fig. 2, G and H). These findings suggest that inhibiting ERK1/2 phosphorylation prevents KIM-1 mRNA upregulation 3 hours post IR AKI by preventing STAT3 phosphorylation at S727 and Y705.

**ERK1/2 Inhibition Suppresses KIM-1 mRNA and Protein 24 Hours Following IR AKI.** After 24 hours, KIM-1 mRNA was ~280-fold higher in the IR group compared with the sham controls (Fig. 3A). Trametinib partially blocked the increase in KIM-1 mRNA (~120-fold higher compared with sham) compared with the IR mice (Fig. 3A). Serum creatinine increased to 1.1 mg/dl in the IR group and pretreatment with trametinib attenuated this rise in SCr after 24 hours (Fig. 3B). STAT3 phosphorylation at S727 and Y705 increased following renal IR injury and trametinib pretreatment blocked these increases (Fig. 3, D, G and H). Chk1 phosphorylation decreased in the IR group after 24 hours and ERK1/2 inhibition had no influence on Chk1 phosphorylation (Fig. 3, D and F). Trametinib inhibited ERK1/2 phosphorylation throughout the 24-hour period after IR surgery (Fig. 3, D and E). The IR group showed a large upregulation in KIM-1 kidney cortex protein that was markedly reduced in the presence of trametinib after 24 hours (Fig. 3C). Because KIM-1 is cleaved from the cell surface, KIM-1 protein was measured in the serum to detect any changes in cleavage regulation (Sabbieietti et al., 2014). Serum KIM-1 protein was high in the IR group and markedly reduced in the

![Fig. 1. ERK1/2 increases KIM-1 mRNA after toxicant exposure in mouse TKPT cells.](image-url)
trametinib group (Fig. 3C). These findings reveal ERK1/2 remains activated 24 hours following IR AKI, which corresponds to increased phosphorylation of STAT3 at S727 and Y705, and leads to increases in KIM-1 mRNA and protein. This correlates with our observations of STAT3 phosphorylation at S727 and Y705 in the trametinib group compared with the IR group in our

**Fig. 2.** ERK1/2 mediates STAT3 phosphorylation and KIM-1 mRNA upregulation following 3 hours of IR AKI. (A) KIM-1 mRNA expression following IR AKI after 3 hours. (B) Serum creatinine was assessed 3 hours after IR AKI. (C) Representative immunoblot of phosphorylated ERK1/2, total ERK1/2, phosphorylated Chk1, and total Chk1 following 3 hours of IR AKI. (D) Densitometry analysis of phosphorylated ERK1/2 compared with total ERK1/2. (E) Densitometry analysis of phosphorylated Chk1 compared with total Chk1. (F) Representative immunoblot of phosphorylated STAT3 (S727 and Y705) and total STAT3 following 3 hours of IR AKI. (G and H) Densitometry analysis of phosphorylated STAT3 (S727 and Y705) compared with total STAT3. Data are represented as mean ± S.E.M., n = 6. Different superscripts indicate statistically significant differences (P < 0.05).
However, it is clear that ERK1/2 and STAT3 are not the only pathways responsible for the later increases in KIM-1 mRNA since the trametinib group is only partially attenuated after 24 hours (Fig. 3A).

**ERK1/2 Increases KIM-1 mRNA in Sepsis-Induced AKI and Requires TLR4.** Previously, we demonstrated LPS-induced AKI requires TLR4-mediated ERK1/2 activation at the initiation of injury to impair kidney function through mitochondrial dysfunction and inflammatory cytokines (Smith et al., 2015). Similarly, partial attenuation of KIM-1 mRNA upregulation through ERK1/2 inhibition prior to LPS administration after 18 hours was observed (Smith et al., 2015). Here, trametinib treatment prevented KIM-1 protein upregulation within the kidney cortex compared with LPS alone after 18 hours (Fig. 4A). ERK1/2 phosphorylation was inhibited in the trametinib + LPS group compared with the control + LPS group, whereas the LPS group was not different from controls (Fig. 4, A and B). To further illustrate that pharmacological ERK1/2 inhibition downregulates KIM-1 expression, ERK1/2 phosphorylation was studied following LPS in TLR4KO mice since TLR4 is required for LPS-induced kidney dysfunction (Smith et al., 2015). TLR4KO mice had reduced ERK1/2 phosphorylation compared with WT mice administered LPS (Fig. 4, D and F). LPS-induced increases in KIM-1 mRNA and KIM-1 protein were attenuated in LPS-treated TLR4KO mice, connecting ERK1/2 activation and KIM-1 to TLR4 (Fig. 4, D and E). For confirmation, TLR4 mRNA expression in the TLR4KO mice was negligible compared with WT TLR4 mRNA expression (Fig. 4C).

**TLR4 Is Not Required for IR-Induced ERK1/2 Phosphorylation and KIM-1 mRNA Upregulation.** To determine if ERK1/2 and KIM-1 are regulated by TLR4 during initiation of injury following IR AKI, TLR4KO mice were subjected to IR surgeries and KIM-1 alterations were observed.
after 3 hours. The WT and TLR4KO mice had similar increases in phosphorylated ERK1/2 following IR AKI compared with their sham controls (Fig. 5, A and C). Interestingly, KIM-1 mRNA was markedly elevated in the TLR4KO IR mice and WT IR mice trended upward (Fig. 5B). The aforementioned findings demonstrate that IR AKI–induced KIM-1 upregulation and ERK1/2 activation are TLR4 independent.

**ERK1/2 Inhibition Decreases KIM-1 mRNA and Nuclear and Cytosolic STAT3 Phosphorylation under Physiologic Conditions.** To determine if ERK1/2 regulates KIM-1 at a physiologic level, naive mice were treated with trametinib or vehicle for 4 hours. Unexpectedly, trametinib-treated mice had ∼55% lower KIM-1 mRNA compared with vehicle control mice (Fig. 6A). The trametinib group had reduced ERK1/2 phosphorylation in the nucleus and cytosol (Fig. 6, G and H). Nuclear STAT3 phosphorylation at sites Y705 and S727 were down in the trametinib group by 55% and 46%, respectively, compared with the vehicle control group (Fig. 6, B–D). Phosphorylated Y705 and S727 on STAT3 in the cytosol were also reduced in the trametinib group (Fig. 6, E and F). To confirm that trametinib was inhibiting nuclear STAT3 phosphorylation, and subsequently KIM-1 mRNA downregulation, cytosol and nuclear fractions were isolated and confirmed for purity using α-tubulin and lamin B1 (Fig. 6H). The purified fractions demonstrated that inhibition of physiologic ERK1/2 phosphorylation results in a decrease in KIM-1 mRNA through reducing STAT3 phosphorylation at Y705 and S727 in the kidney. By decreasing active STAT3 within the nucleus there is potential for less KIM-1 promoter binding, resulting in lower KIM-1 mRNA expression.

**Discussion**

In this study, ERK1/2 was identified as a regulator of KIM-1 expression. ERK1/2 inhibition prevented KIM-1 transcription in vitro following toxicant exposure, and attenuated increases...
in KIM-1 mRNA and protein in IR AKI. STAT3 phosphorylation at S727 and Y705 decreased as a result of ERK1/2 inhibition, leading to less KIM-1 expression. In sepsis-induced AKI, TLR4 was required for activation of ERK1/2 and KIM-1 upregulation. In contrast, ERK1/2 phosphorylation following IR AKI was not dependent on TLR4. Interestingly, in naive mice ERK1/2 regulates KIM-1 mRNA by physiologic STAT3 phosphorylation in the nucleus. We suggest ERK1/2 regulates renal KIM-1 expression at a physiologic level and initially during pathologic renal injury by phosphorylation of STAT3.

The discovery that KIM-1 is the most upregulated gene following AKI led to an increase in KIM-1 renal research (Ichimura et al., 1998; Vaidya et al., 2006, 2010). Ajay et al. (2014) explored the signaling pathway that results in upregulation of renal KIM-1 mRNA. They reported KIM-1 transcriptional regulation by Chk1-STAT3 interaction following AKI-induced DNA damage. Chk1 was revealed as an upstream kinase of STAT3 and phosphorylation at S727 and Y705 on STAT3 was required for KIM-1 upregulation (Ajay et al., 2014).

Phosphorylated STAT3 increased following AKI and was found to bind to the KIM-1 promoter, therefore increasing KIM-1 mRNA and protein (Ajay et al., 2014). While our studies support the work of Ajay et al. (2014), important differences were observed: 1) Chk1 phosphorylation did not increase following IR AKI after 3 and 24 hours, 2) ERK1/2 was responsible for the STAT3 phosphorylation after IR, and 3) our IR experimental design used mice rather than rats for AKI. Chk1 phosphorylation did not increase in the renal cortex in our experiments; however, KIM-1 mRNA and renal dysfunction was observed. Nevertheless, STAT3 phosphorylation was verified to increase following renal injury, and a reduction in phosphorylated STAT3 attenuated KIM-1 mRNA. However, ERK1/2 was demonstrated as the key initial regulator of STAT3 phosphorylation following renal injury, rather than Chk1.

We previously published work demonstrating that inhibiting the rapid activation of ERK1/2 following renal injury prevents and/or attenuates injury and dysfunction through restoration of mitochondrial function, renal microvascular perfusion, and attenuation of proinflammatory cytokines.
KIM-1 is expressed at very low levels in healthy noninjured kidneys, with complete attenuation of SCr elevation compared with the IR group. KIM-1 protein levels were substantially lower in the trametinib-treated mice, both in the kidney cortex and medulla. Twenty-four hours following IR AKI, a partial reduction in KIM-1 mRNA was detected in the trametinib group, indicating decreased expression of KIM-1 mRNA. Phosphorylated Chk1 was not altered in the nuclear and cytosolic fractions of the renal cortex and medulla, suggesting Chk1 phosphorylation is a late event in kidney injury.

Previous experiments demonstrated activated ERK1/2 phosphorylates STAT3 at S727, while at the same time decreasing STAT3 Y705 phosphorylation (Booz et al., 2003; Kanai et al., 2003; Gough et al., 2013). However, in our study both S727 and Y705 phosphorylation increased following IR injury and decreased with pretreatment with trametinib, suggesting ERK1/2 is responsible for phosphorylating both sites. Twenty-four hours following IR AKI, a partial reduction of KIM-1 mRNA in the trametinib group was observed, along with complete attenuation of SCr elevation compared with the IR group. KIM-1 protein levels were substantially lower in the trametinib-treated mice, both in the kidney cortex and medulla since KIM-1 can be detected in the blood. This occurrence has been recognized due to the loss of cell polarity, microvascular permeability dysfunction, disruption of cell-cell adhesion junctions, and basement membrane cell detachment (Sabbisetti et al., 2014; Tian et al., 2017).

ERK1/2 phosphorylation was found to regulate KIM-1 expression in a second AKI model. LPS-induced AKI increased ERK1/2 phosphorylation and KIM-1 protein, whereas trametinib prevented ERK1/2 activation and attenuated the KIM-1 protein increase. Further characterization of the ERK1/2-KIM-1 pathway was demonstrated by utilization of TLR4KO mice. TLR4 is required for LPS-induced ERK1/2 phosphorylation and downstream KIM-1 mRNA upregulation (Smith et al., 2015). ERK1/2 is rapidly phosphorylated following LPS after 1 and 3 hours; however, in this study after 18 hours post-LPS phosphorylated ERK1/2 was not different than the control group, most likely stemming from a prompt compensatory mechanism. Nonetheless, 18 hours after cecal ligation and puncture, which is a slower developing sepsis model, ERK1/2 phosphorylation is still highly phosphorylated compared with controls (Smith et al., 2015, 2016). To verify that TLR4 signaling was not regulating KIM-1 expression directly, the TLR4KO mice underwent IR AKI and were compared with the WT mice. There were no differences in ERK1/2 phosphorylation between the TLR4KO IR group and the WT IR group, and the TLR4KO group had increased KIM-1 mRNA. Thus, TLR4 is required for LPS-induced ERK1/2 activation and increase in KIM-1 mRNA; however, in IR AKI TLR4 is not required since ERK1/2 is activated via other non-TLR4 upstream pathways. Therefore, we view ERK1/2 phosphorylation as a key event controlling KIM-1 regulation, which is activated through different pathways in different diseases.

To determine if ERK1/2 regulated KIM-1 at a physiologic level, trametinib was administered to naive mice. Although KIM-1 is expressed at very low levels in healthy noninjured kidneys, there is a physiologic basal level of detection (Ichimura et al., 1998; van Timmeren et al., 2006). In the absence of an injury, inhibiting physiologic ERK1/2 phosphorylation resulted in the downregulation of KIM-1 mRNA. This observation correlates with our in vitro results that demonstrated trametinib treatment in mouse TKPT cells decreased KIM-1 mRNA. Phosphorylated Chk1 was not altered in the trametinib-treated mice (data not shown). ERK1/2 phosphorylation was inhibited in the nuclear and cytosolic fractions of the kidney cortex, which decreased STAT3 Y705 and S727 phosphorylation in the nucleus. Therefore, less active STAT3 is able to bind to the KIM-1 promoter, corresponding to the KIM-1 mRNA reduction observed.

We have provided evidence that STAT3 phosphorylated at Y705 and S727 is partially responsible for renal KIM-1 upregulation, and that ERK1/2 involvement is upstream of STAT3. These findings provide further evidence that initial ERK1/2 activation is a key regulator of various pathways following renal injury, which may lead to the discovery of potential pharmacological-based therapies.

Authorship Contributions

Participated in research design: Collier, Schnellmann.
Conducted experiments: Collier.
Wrote data analysis: Collier.
Wrote or contributed to the writing of the manuscript: Collier, Schnellmann.

References


